Skip to main content

Pfizer cash flow statement

  • PFE · NYSE
  • Pharmaceuticals
  • S&P 500
$28.89+0.21%Close 13 Nov 2026 · Market value $164.8B

In fiscal 2025 (the year to 31 Dec 2025), Pfizer generated $11.70B of operating cash flow and $9.07B of free cash flow, after $2.63B of capital expenditure.

From Pfizer's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Pfizer cash flow statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income$8.14B$8.10B$8.63B$8.26B$10.01B$14.57B$22.00B$9.13B$6.96B$7.21B$21.31B$11.15B$16.03B$9.16B$21.98B$31.37B$2.12B$8.03B$7.77B$4.03B
Depreciation & amortization$5.20B$5.09B$4.76B$8.40B$8.70B$7.39B$6.31B$5.54B$5.16B$5.76B$6.27B$6.15B$5.75B$4.68B$5.19B$5.06B$6.29B$7.01B$6.59B$6.50B
Stock-based compensation$437.0M$384.0M$349.0M$405.0M$419.0M$481.0M$523.0M$586.0M$669.0M$691.0M$840.0M$923.0M$687.0M$755.0M$1.18B$872.0M$525.0M$877.0M$799.0M$1.11B
Operating cash flow$13.35B$18.24B$16.59B$11.45B$20.24B$16.75B$17.68B$17.08B$14.69B$16.19B$16.80B$15.83B$12.59B$14.40B$32.58B$29.27B$8.70B$12.74B$11.70B$14.17B
Operating cash flow margin27.6%37.8%33.7%17.6%33.2%30.6%34.3%34.4%30.1%30.7%32.0%38.8%30.8%34.6%40.1%28.9%14.6%20.0%18.7%22.3%
Capital expenditures$1.88B$1.70B$1.21B$1.51B$1.66B$1.33B$1.21B$1.20B$1.40B$1.82B$1.96B$1.98B$2.05B$2.23B$2.71B$3.24B$3.91B$2.91B$2.63B$2.39B
Acquisitions$464.0M$1.18B$43.12B$273.0M$3.28B$1.05B$15.00M$195.0M$16.47B$18.37B$1.00B$0.00$10.86B$0.00$0.00$23.00B$43.43B$0.00$6.93B—
Free cash flow$11.47B$16.54B$15.38B$9.94B$18.58B$15.42B$16.48B$15.88B$13.29B$14.37B$14.85B$13.84B$10.54B$12.18B$29.87B$26.03B$4.79B$9.84B$9.07B$11.79B
Free cash flow margin23.7%34.2%31.2%15.3%30.4%28.2%31.9%32.0%27.2%27.2%28.3%33.9%25.8%29.2%36.7%25.7%8.0%15.5%14.5%18.5%
Free cash flow per share$1.65$2.45$2.18$1.23$2.36$2.05$2.39$2.47$2.12$2.33$2.45$2.32$1.86$2.16$5.23$4.54$0.84$1.73$1.59$2.06
Dividends paid$7.97B$8.54B$5.55B$6.09B$6.23B$6.53B$6.58B$6.61B$6.94B$7.32B$7.66B$7.98B$8.04B$8.44B$8.73B$8.98B$9.25B$9.51B$9.77B$9.79B
Gross share repurchases$9.99B$500.0M$0.00$1.00B$9.00B$8.23B$16.29B$5.00B$6.16B$5.00B$5.00B$12.20B$8.87B$0.00$0.00$2.00B$0.00$0.00——
Stock issuance proceeds————$153.0M$568.0M$1.75B$1.00B$1.26B$1.02B$862.0M$1.26B$394.0M$425.0M——————
Net share repurchases$9.99B$500.0M$0.00$1.00B$8.85B$7.66B$14.54B$4.00B$4.90B$3.98B$4.14B$10.94B$8.47B−$425.0M$0.00$2.00B$0.00$0.00——
Cash interest paid$643.0M$782.0M$935.0M$2.15B$2.08B$1.87B$1.73B$1.55B$1.30B$1.45B$1.52B$1.31B$1.59B$1.64B$1.47B$1.44B$2.21B$3.23B$2.74B$2.81B
Free cash flow after SBC$11.04B$16.15B$15.03B$9.54B$18.16B$14.94B$15.96B$15.30B$12.62B$13.68B$14.01B$12.92B$9.86B$11.42B$28.69B$25.16B$4.27B$8.96B$8.28B$10.68B

Quarterly

Pfizer cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income−$3.37B$3.12B$41.00M$4.46B$410.0M$2.97B$2.91B$3.54B−$1.65B$2.69B−$248.0M$3.24B
Depreciation & amortization$1.67B$1.74B$1.73B$1.75B$1.79B$1.62B$1.63B$1.66B$1.69B$1.61B$1.62B$1.58B
Stock-based compensation$121.0M$220.0M$206.0M$274.0M$177.0M$170.0M$203.0M$201.0M$225.0M$272.0M$249.0M$362.0M
Operating cash flow$5.24B$1.09B−$1.78B$6.71B$6.72B$2.33B−$582.0M$4.60B$5.35B$2.62B$835.0M$5.38B
Operating cash flow margin38.8%7.3%−13.4%37.9%37.8%17.0%−4.0%27.6%30.5%18.1%5.6%32.4%
Capital expenditures$1.04B$704.0M$637.0M$651.0M$917.0M$564.0M$618.0M$602.0M$845.0M$436.0M$533.0M$573.0M
Acquisitions$43.41B——$0.00$0.00———————
Free cash flow$4.20B$386.0M−$2.42B$6.06B$5.80B$1.77B−$1.20B$4.00B$4.50B$2.18B$302.0M$4.80B
Free cash flow margin31.1%2.6%−18.2%34.3%32.7%12.9%−8.2%24.0%25.6%15.1%2.0%29.0%
Free cash flow per share$0.74$0.07−$0.42$1.06$1.02$0.31−$0.21$0.70$0.79$0.38$0.05$0.83
Dividends paid$2.31B$2.37B$2.38B$2.38B$2.38B$2.44B$2.44B$2.44B$2.44B$2.44B$2.45B$2.45B
Gross share repurchases$0.00———————————
Net share repurchases$0.00———————————
Cash interest paid$1.06B$415.0M$1.14B$280.0M$1.39B$353.0M$1.13B$275.0M$981.0M$293.0M$1.25B$283.0M
Free cash flow after SBC$4.08B$166.0M−$2.62B$5.79B$5.63B$1.60B−$1.40B$3.80B$4.28B$1.91B$53.00M$4.44B

The main figures as JSON and plain text. See data and methodology.

PFE in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.